StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Equities research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other equities analysts have also commented on CTSO. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.03 on Friday. The firm’s fifty day simple moving average is $1.04 and its 200 day simple moving average is $1.05. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The firm has a market capitalization of $56.32 million, a price-to-earnings ratio of -2.86 and a beta of 0.61.

Hedge Funds Weigh In On Cytosorbents

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in shares of Cytosorbents in the fourth quarter worth $30,000. Renaissance Technologies LLC increased its position in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Northern Trust Corp raised its stake in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Cytosorbents during the fourth quarter worth about $99,000. Finally, Geode Capital Management LLC lifted its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.